Clinical trial NCT00118898 (phase 3, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: abacavir/lamivudine, atazanavir, efavirenz, emtricitabine/tenofovir disoproxil fumarate, ritonavir, abacavir/lamivudine placebo, emtricitabine/tenofovir disoproxil fumarate placebo
SMILES: [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  HIV-infected. A resistance assay must be obtained if the participant has evidence of
             recent infection. More information on this criterion can be found in the protocol.

          -  Antiretroviral naive, defined as 7 days or less of ARV treatment at any time prior to
             study entry. Participants who have received ARVs as part of postexposure prophylaxis
             or who have received an investigational drug that was not an NRTI, NNRTI, or PI are
             eligible for this study.

          -  HIV viral load greater than 1,000 copies/ml within 90 days prior to study entry

          -  Certain laboratory values obtained within 30 days prior to study entry. More
             information on this criterion can be found in the protocol

          -  Willing to use acceptable forms of contraception

          -  Parent or guardian able and willing to provide written informed consent, if applicable

          -  Hepatitis B surface antigen (HBsAg) negative at study entry

        Exclusion Criteria:

          -  Immunomodulators (e.g., interleukins, interferons, cyclosporine), HIV vaccine,
             systemic cytotoxic chemotherapy, or investigational therapy within 30 days prior to
             study entry. Individuals receiving either stable physiologic glucocorticoid doses,
             corticosteroids for acute therapy for pneumocystis pneumonia, or a short course (2
             weeks or less) of pharmacologic glucocorticoid therapy will not be excluded.

          -  Known allergy/sensitivity to study drugs or their formulations

          -  Active alcohol or drug use that, in the opinion of the investigator, would interfere
             with adherence to study requirements

          -  Serious illness requiring systemic treatment or hospitalization. Patients who have
             completed therapy or are clinically stable on therapy for at least 7 days prior to
             study entry are not excluded.

          -  Known clinically relevant cardiac conduction system disease

          -  Requirement for any current medications that are prohibited with any study treatment.

          -  Evidence of any major drug resistance-associated mutation on any genotype or evidence
             of significant resistance on any phenotype performed at any time prior to study entry.

          -  Current imprisonment or involuntary incarceration for psychiatric or physical (e.g.,
             infectious disease) illness

          -  Breastfeeding. Women who become pregnant during the study will be unblinded and
             required to permanently discontinue their study regimens.